What is it about?
In patients with more than two sites of metastatic disease, the progression free survival was almost the same compared with the pivotal trial.
Featured Image
Why is it important?
It is a good alternative and tolerate in first line treatment of RCC
Perspectives
The patients in Latin America have important tumor burden. They have similar toxicity. And the outcomes are almost the same of those report in the pivotal study. The access it is difficult in our countries... so this drug it is a good option in first line for our patients.
Paula Cabrera
Instituto Nacional de Cancerología, México
Read the Original
This page is a summary of: Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma, OncoTargets and Therapy, September 2016, Dove Medical Press,
DOI: 10.2147/ott.s109445.
You can read the full text:
Contributors
The following have contributed to this page
